Health-care stocks make up about 12% of Standard & PoorUs 500-stock index, so putting at least that much of your U.S. stock portfolio in the sector makes sense. But if you're shopping for a health-care sector fund, keep in mind that other funds in your portfolio probably have a big dose of health stocks already, so factor that into your calculations.
Our favorite health-care fund is T. Rowe Price Health Sciences (symbol PRHSX; 800-638-5660). Under manager Kris Jenner, a graduate of Johns Hopkins School of Medicine, the no-load fund posted an annualized return of 18% over the past five years to October 1, outpacing the Dow Jones Health Care index by an average of eight percentage points per year.
Large drug companies dominate the major health-care indexes, and just two stocks, Johnson & Johnson and Pfizer, account for as much as 20% of some measures. Jenner's portfolio, by contrast, tilts toward midsize firms. Roughly one-third of the fund is invested in biotech stocks, and its allocation to Big Pharma is low, at about 25% of assets. We think that's about right. The fund charges a reasonable 0.87% annually to cover expenses.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Schwab Health Care (SWHFX; 800-435-4000), which uses a computer model to pick stocks, is another top-performing, low-cost fund. Lately, the model has been favoring shares of large companies, and Big Pharma dominates the top ten holdings, which make up about half the fund's assets (Schering-Plough, Merck and Pfizer are among the four biggest holdings). But it's hard to argue with the fund's record -- a 19% annualized return over five years. The expense ratio is 0.84%.
If you prefer an indexed approach to health stocks, we suggest two cheap exchange-traded funds. Annual expenses for Vanguard Health Care (VHT) and Health Care Select Sector SPDR (XLV) are 0.25% and 0.24%, respectively. SPDR S&P Biotech (XBI) is a good way to add some biotech to your existing health-care holdings, but donUt get carried away. A 5% allocation is more than enough for most investors. The fund charges 0.35% annually for expenses.
-
Jabil Stock Pops After a Beat-And-Raise QuarterJabil stock is higher Wednesday after the electronics firm beat earnings expectations and raised its full-year outlook. Here's what you need to know.
-
UBS Global's Solita Marcelli: It's a Green Light for U.S. Stocks in 2025A strong economy, rate cuts and continued AI spending should support stocks in the new year, says UBS Global's chief investment officer, Americas.
-
Best Banks for High-Net-Worth Clients 2024wealth management These banks welcome customers who keep high balances in deposit and investment accounts, showering them with fee breaks and access to financial-planning services.
-
Stock Market Holidays in 2024 and 2025: NYSE, NASDAQ and Wall Street HolidaysMarkets When are the stock market holidays? Here, we look at which days the NYSE, Nasdaq and bond markets are off in 2024 and 2025.
-
Stock Market Trading Hours: What Time Is the Stock Market Open Today?Markets When does the market open? While the stock market does have regular hours, trading doesn't necessarily stop when the major exchanges close.
-
Bogleheads Stay the CourseBears and market volatility don’t scare these die-hard Vanguard investors.
-
The Current I-Bond Rate Until May Is Mildly Attractive. Here's Why.Investing for Income The current I-bond rate is active until November 2024 and presents an attractive value, if not as attractive as in the recent past.
-
What Are I-Bonds? Inflation Made Them Popular. What Now?savings bonds Inflation has made Series I savings bonds, known as I-bonds, enormously popular with risk-averse investors. So how do they work?
-
This New Sustainable ETF’s Pitch? Give Back Profits.investing Newday’s ETF partners with UNICEF and other groups.
-
As the Market Falls, New Retirees Need a Planretirement If you’re in the early stages of your retirement, you’re likely in a rough spot watching your portfolio shrink. We have some strategies to make the best of things.
